Royal Bank Of Canada Reaffirms Outperform Rating for AbbVie (NYSE:ABBV)

AbbVie (NYSE:ABBV)‘s stock had its “outperform” rating restated by stock analysts at Royal Bank Of Canada in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $280.00 price target on the stock. Royal Bank Of Canada’s price target points to a potential upside of 1.21% from the company’s current price.

Other equities analysts have also recently issued research reports about the company. Argus upped their price target on AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. Guggenheim reiterated a “buy” rating and set a $288.00 target price on shares of AbbVie in a research report on Friday. Weiss Ratings upgraded AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday. Cantor Fitzgerald lifted their price objective on AbbVie from $285.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, October 8th. Finally, Canaccord Genuity Group increased their target price on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $277.18.

AbbVie Price Performance

AbbVie stock traded down $4.48 during midday trading on Tuesday, reaching $276.65. The stock had a trading volume of 1,887,364 shares, compared to its average volume of 6,390,898. AbbVie has a twelve month low of $190.75 and a twelve month high of $283.43. The firm has a market cap of $488.77 billion, a price-to-earnings ratio of 78.17, a PEG ratio of 1.26 and a beta of 0.24. The firm’s fifty day simple moving average is $259.79 and its two-hundred day simple moving average is $237.39.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts predict that AbbVie will post 13.94 EPS for the current fiscal year.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

Hedge Funds Weigh In On AbbVie

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. McGlone Suttner Wealth Management Inc. boosted its stake in AbbVie by 0.6% during the 3rd quarter. McGlone Suttner Wealth Management Inc. now owns 12,230 shares of the company’s stock valued at $3,199,000 after purchasing an additional 70 shares during the last quarter. Sivik Global Healthcare LLC lifted its position in shares of AbbVie by 46.7% during the third quarter. Sivik Global Healthcare LLC now owns 22,000 shares of the company’s stock valued at $5,755,000 after purchasing an additional 7,000 shares in the last quarter. Compass Financial Group INC SD grew its position in AbbVie by 15.3% in the 3rd quarter. Compass Financial Group INC SD now owns 1,648 shares of the company’s stock worth $431,000 after purchasing an additional 219 shares in the last quarter. Sax Wealth Advisors LLC increased its position in shares of AbbVie by 40.5% during the third quarter. Sax Wealth Advisors LLC now owns 16,271 shares of the company’s stock valued at $4,256,000 after acquiring an additional 4,692 shares during the last quarter. Finally, Fermata Advisors LLC increased its position in shares of AbbVie by 23.7% during the 3rd quarter. Fermata Advisors LLC now owns 1,124 shares of the company’s stock valued at $294,000 after purchasing an additional 215 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and set a $280 price target, indicating continued confidence in AbbVie’s outlook, although the target implies only modest near-term upside. TickerReport article
• Positive Sentiment: Skyrizi and Rinvoq are expected to be the primary drivers of third-quarter revenue growth, helping offset the continued decline of Humira. Long-term data presented at ACG 2026 also support the durability of these products. Yahoo Finance article
• Positive Sentiment: Investors remain focused on AbbVie’s pipeline expansion, including a recently completed acquisition and a new FDA approval that could create another billion-dollar growth opportunity. 247WallSt article
• Neutral Sentiment: AbbVie was highlighted in broader discussions of pharmaceutical merger activity, as large drugmakers pursue acquisitions to address upcoming patent cliffs. This supports sector interest but does not provide a company-specific catalyst by itself. ETF Trends article
• Negative Sentiment: Humira’s ongoing erosion and increasing competition in immunology remain key risks. In addition, AbbVie’s elevated valuation and the limited upside to RBC’s target may encourage investors to lock in gains after the stock’s recent rally. Motley Fool article

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.